Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) tinted loss of -2.11% (-0.1 points) to US$4.64. The volume of 0.53 Million shares climbed down over an trading activity of 1.79 Million shares. EPS ratio determined by looking at last 12 month figures is -1.87. Over the same time span, the stock marked US$9.44 as its best level and the lowest price reached was US$1.11. The corporation has a market cap of US$33.75 Million.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 1.1 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Cronos Group Inc. (NASDAQ:CRON) is worth US$3.52 Billion and has recently risen 3.97% to US$20.45. The latest exchange of 17.06 Million shares is above its average trading activity of 15.47 Million shares. The day began at US$20.06 but the price moved to US$19.9 at one point during the trading and finally capitulating to a session high of US$20.68. The stock tapped a 52-week high of US$25.1 while the mean 12-month price target for the shares is US$0.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 21.06, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 16.38%, it carries an earnings per share ratio of -0.03.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.